Apichope Pharmaceutical Group Co., Ltd. (300723.SZ) announced that its wholly-owned subsidiary, Guangzhou Lianrui Pharmaceutical Co., Ltd., recently received the Drug Registration Certificate for Sodium Valproate Concentrated Injection Solution issued by the National Medical Products Administration.
The acquisition of this registration certificate signifies the company's qualification to market this specification of the drug in the domestic market. It will further diversify Apichope's product pipeline and categories, enhancing its competitiveness in the chronic disease medication sector.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments